Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
8
×
national blog main
boston blog main
clinical trials
boston
boston top stories
fda
alnylam pharmaceuticals
drugs
rna interference
biotech
national top stories
patisiran
alexion pharmaceuticals
aminolevulinic acid
deals
givosiran
hereditary transthyretin amyloidosis
new york blog main
new york top stories
onpattro
paul matteis
san francisco blog main
san francisco top stories
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akcea therapeutics
akin akinc
alirocumab
amgen
amyotrophic lateral sclerosis (als)
andrew fire
autoimmune disorders
boehringer ingelheim
cannabidiol
complement system
craig mello
crispr
cystic fibrosis
What
pharmaceuticals
8
×
drug
alnylam
medicine
medicines
data
fda
rna
rnai
ago
approved
disease
interference
market
new
ok
pharma
second
seek
speedy
weeks
afternoon
alnylam’s
alternative
approval
autoimmune
based
battle
candidate
cannabis
caught
causing
cf
cholesterol
cleared
crisis
cystic
deal
derivative
developer
Language
unset
unknown
Current search:
xconomy.com
×
" life sciences "
×
pharmaceuticals
×
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
4 years ago
Jeff Leiden, Who Shaped Vertex Into a CF Force, to Switch Roles
@xconomy.com
5 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug